Language of the Report – English
Sin embargo, el informe puede estar disponible en español por un costo adicional.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Market Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Snapshot
6.1 Latin America
6.2 By Country
7 Industry Opportunities and Challenges
8 Latin America Hereditary Angioedema Therapeutic Market Analysis
8.1 Key Industry Highlights
8.2 Latin America Hereditary Angioedema Therapeutic Historical Market (2019-2025)
8.3 Latin America Hereditary Angioedema Therapeutic Market Forecast (2026-2035)
8.4 Latin America Hereditary Angioedema Therapeutic Market by Drug Class
8.4.1 C1-Esterase Inhibitor
8.4.1.1 Market Share
8.4.1.2 Historical Trend (2019-2025)
8.4.1.3 Forecast Trend (2026-2035)
8.4.2 Bradykinin B2 Receptor Antagonist
8.4.2.1 Market Share
8.4.2.2 Historical Trend (2019-2025)
8.4.2.3 Forecast Trend (2026-2035)
8.4.3 Kallikrein Inhibitor
8.4.3.1 Market Share
8.4.3.2 Historical Trend (2019-2025)
8.4.3.3 Forecast Trend (2026-2035)
8.4.4 Others
8.5 Latin America Hereditary Angioedema Therapeutic Market by Treatment Type
8.5.1 Prophylaxis Treatment
8.5.1.1 Market Share
8.5.1.2 Historical Trend (2019-2025)
8.5.1.3 Forecast Trend (2026-2035)
8.5.2 On-Demand Treatment
8.5.2.1 Market Share
8.5.2.2 Historical Trend (2019-2025)
8.5.2.3 Forecast Trend (2026-2035)
8.6 Latin America Hereditary Angioedema Therapeutic Market by Route of Administration
8.6.1 Intravenous
8.6.1.1 Market Share
8.6.1.2 Historical Trend (2019-2025)
8.6.1.3 Forecast Trend (2026-2035)
8.6.2 Subcutaneous
8.6.2.1 Market Share
8.6.2.2 Historical Trend (2019-2025)
8.6.2.3 Forecast Trend (2026-2035)
8.6.3 Oral
8.6.3.1 Market Share
8.6.3.2 Historical Trend (2019-2025)
8.6.3.3 Forecast Trend (2026-2035)
8.7 Latin America Hereditary Angioedema Therapeutic Market by Country
8.7.1 Market Share
8.7.1.1 Brazil
8.7.1.2 Argentina
8.7.1.3 Mexico
8.7.1.4 Others
9 Regional Analysis
9.1 Brazil
9.1.1 Historical Trend (2019-2025)
9.1.2 Forecast Trend (2026-2035)
9.2 Argentina
9.2.1 Historical Trend (2019-2025)
9.2.2 Forecast Trend (2026-2035)
9.3 Mexico
9.3.1 Historical Trend (2019-2025)
9.3.2 Forecast Trend (2026-2035)
10 Market Dynamics
10.1 SWOT Analysis
10.1.1 Strengths
10.1.2 Weaknesses
10.1.3 Opportunities
10.1.4 Threats
10.2 Porter’s Five Forces Analysis
10.2.1 Supplier’s Power
10.2.2 Buyers Powers
10.2.3 Threat of New Entrants
10.2.4 Degree of Rivalry
10.2.5 Threat of Substitutes
10.3 Key Indicators for Demand
10.4 Key Indicators for Price
11 Value Chain Analysis
12 Competitive Landscape
12.1 Market Structure
12.2 Key Company Profiles
12.2.1 BioCryst Pharmaceuticals, Inc.
12.2.1.1 Company Overview
12.2.1.2 Product Portfolio
12.2.1.3 Demographic Reach and Achievements
12.2.1.4 Certifications
12.2.2 Takeda Pharmaceutical Company Limited
12.2.2.1 Company Overview
12.2.2.2 Product Portfolio
12.2.2.3 Demographic Reach and Achievements
12.2.2.4 Certifications
12.2.3 CSL Limited
12.2.3.1 Company Overview
12.2.3.2 Product Portfolio
12.2.3.3 Demographic Reach and Achievements
12.2.3.4 Certifications
12.2.4 Ionis Pharmaceuticals, Inc.
12.2.4.1 Company Overview
12.2.4.2 Product Portfolio
12.2.4.3 Demographic Reach and Achievements
12.2.4.4 Certifications
12.2.5 BioMarin
12.2.5.1 Company Overview
12.2.5.2 Product Portfolio
12.2.5.3 Demographic Reach and Achievements
12.2.5.4 Certifications
12.2.6 Others
13 Industry Events and Developments